Evidence map›Paper›PMID 33972918›Full record

ArticleNanotheranostics2021

Europium sulfide nanoprobes predict antiretroviral drug delivery into HIV-1 cell and tissue reservoirs.

Jonathan Herskovitz, Mahmudul Hasan, Jatin Machhi, Insiya Mukadam, Brendan M Ottemann, James R Hilaire, Christopher Woldstad, JoEllyn McMillan, Yutong Liu, Javier Seravalli and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanotheranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Jonathan HerskovitzDepartment of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Mahmudul HasanDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198 USA.
Jatin MachhiDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198 USA.
Insiya MukadamDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198 USA.
Brendan M OttemannDepartment of Otorhinolaryngology, University of Kansas Medical Center, Kansas City, KS 66213 USA.
James R HilaireDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198 USA.
Christopher WoldstadBrain Health Imaging Institute, Weill Cornell Medicine, New York, NY 10065 USA.
JoEllyn McMillanDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198 USA.
Yutong LiuDepartment of Radiology, University of Nebraska Medical Center, Omaha, NE 68198 USA.
Javier SeravalliDepartment of Biochemistry, University of Nebraska Lincoln, Lincoln, NE 68588 USA.
Anandakumar SarellaNebraska Center for Materials and Nanoscience, University of Nebraska Lincoln, Lincoln, NE 68588 USA.
Howard E GendelmanDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198 USA.
Bhavesh D KevadiyaDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198 USA.
University of Nebraska Medical Center · US

Funding

Pharmacokinetics and Drug-Drug InteractionsP01DA028555 · NIDA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BOSKA, MICHAEL DOUGLAS · 2010 to 2019
$16.8M
Combined Molecular Excision Therapy (CMET) for Eliminating HIV-1R01MH115860 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 2017 to 2021
$3.5M
Neuroimmunology of Disease Training ProgramT32NS105594 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Aditya N Bade, Howard E Gendelman · 2018 to 2026
$1.4M
NIDA NIH HHS P01 DA028555NIMH NIH HHS R01 MH115860NINDS NIH HHS T32 NS105594
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-HIV AgentsDrug CarriersEuropiumHIV InfectionsMagnetic Resonance ImagingNanoparticlesRilpivirineSingle Photon Emission Computed Tomography Computed TomographySulfidesAnimalsCell LineDelayed-Action PreparationsHIV-1HumansMaleMiceAnti-HIV AgentsDelayed-Action PreparationsDrug CarriersEuropiumRilpivirineSulfidesantiretroviraleuropiumHIV-1molecular imagingnanotheranosticsSPECT-CT

Identifiers

PMID33972918
PMCPMC8100756
OpenAlexW3159154126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.